摘要
目的:评价重组人粒细胞集落刺激因子(G_CSF)在治疗肾移植后白细胞减少症中的效果及安全性。方法:应用G_CSF治疗肾移植后白细胞减少症10例(男性6例,女性4例,年龄38±s11a),每例注射G_CSF150μg,sc,qd,直至白细胞计数>4×109/L。结果:10例接受G_CSF的剂量为225±106μg,治疗前白细胞计数基值为(2.2±0.4)×109/L,治疗后白细胞峰值为(10.6±2.6)×109/L(P<0.01),开始治疗至出现峰值时间为3.6±1.3d,治疗前血清肌酐为235±135μmol/L,治疗后2wk内最高血清肌酐为234±125μmol/L(P>0.05)。结论:G_CSF治疗肾移植后白细胞减少症疗效显著。
AIM: To study the therapeutic effects and the safety of granulocyte colony-stimulating factor (G-CSF) in treating renal allograft recipients with leukopenia. METHODS: Ten patients (M6, F4; age 38±s 11 a) with leukopenia after kidney transplantation were treated with G-CSF 150 μg, sc, qd until the desired WBC count of >4×109/L was achieved. RESULTS: Ten patients received 225±106 μg G-CSF. The mean WBC nadir was (2.2±0.4)×109/L with peak WBC count of (10.6±2.6)×109/L following treatment(P<0.01). The time to peak WBC after initiation of treatment was 3.6±1.3 d. The mean pretreatment serum creatinine level was 235±135 μmol/L and peak serum creatinine in 2 wk following treatment was 234±125 μmol/L (P>0.05). CONCLUSION: G-CSF is an effective treatment for leukopenia in kidney transplant patients and does not precipitate or aggravate allograft rejection.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
1998年第4期224-226,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
重组粒细胞集落刺激因子
肾移植
白细胞减少症
recombinant granulocyte colony-stimulating factor
kidney transplantation
leukopenia